WO2013122553A1 - Formulation pharmaceutique comprenant un inhibiteur d'atpase et procédé de production de cette formulation - Google Patents

Formulation pharmaceutique comprenant un inhibiteur d'atpase et procédé de production de cette formulation Download PDF

Info

Publication number
WO2013122553A1
WO2013122553A1 PCT/TR2013/000059 TR2013000059W WO2013122553A1 WO 2013122553 A1 WO2013122553 A1 WO 2013122553A1 TR 2013000059 W TR2013000059 W TR 2013000059W WO 2013122553 A1 WO2013122553 A1 WO 2013122553A1
Authority
WO
WIPO (PCT)
Prior art keywords
cellulose
sodium
sucrose
agent
calcium
Prior art date
Application number
PCT/TR2013/000059
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013122553A1 publication Critical patent/WO2013122553A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques comprenant un inhibiteur d'ATPase conçu pour être utilisé pour traiter des maladies associées à un trouble de la sécrétion d'acide gastrique.
PCT/TR2013/000059 2012-02-14 2013-02-14 Formulation pharmaceutique comprenant un inhibiteur d'atpase et procédé de production de cette formulation WO2013122553A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/01599 2012-02-14
TR201201599 2012-02-14

Publications (1)

Publication Number Publication Date
WO2013122553A1 true WO2013122553A1 (fr) 2013-08-22

Family

ID=48142060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000059 WO2013122553A1 (fr) 2012-02-14 2013-02-14 Formulation pharmaceutique comprenant un inhibiteur d'atpase et procédé de production de cette formulation

Country Status (1)

Country Link
WO (1) WO2013122553A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224728A (zh) * 2014-08-29 2014-12-24 济南康和医药科技有限公司 一种埃索美拉唑肠溶微丸及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025204A1 (fr) * 1992-06-16 1993-12-23 Ethypharm Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention
US20010053387A1 (en) * 1997-05-23 2001-12-20 Hamied Yusuf Khwaja Benzimidazole pharmaceutical composition and process of prepatation
WO2012017074A1 (fr) * 2010-08-06 2012-02-09 Valpharma S.P.A. Formulations pharmaceutiques orales d'ésoméprazole sous la forme de comprimés mups (multi unit pellets system)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025204A1 (fr) * 1992-06-16 1993-12-23 Ethypharm Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention
US20010053387A1 (en) * 1997-05-23 2001-12-20 Hamied Yusuf Khwaja Benzimidazole pharmaceutical composition and process of prepatation
WO2012017074A1 (fr) * 2010-08-06 2012-02-09 Valpharma S.P.A. Formulations pharmaceutiques orales d'ésoméprazole sous la forme de comprimés mups (multi unit pellets system)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224728A (zh) * 2014-08-29 2014-12-24 济南康和医药科技有限公司 一种埃索美拉唑肠溶微丸及其制备方法
CN104224728B (zh) * 2014-08-29 2016-10-19 济南康和医药科技有限公司 一种埃索美拉唑肠溶微丸及其制备方法

Similar Documents

Publication Publication Date Title
CA2315261C (fr) Forme posologique pharmaceutique orale a liberation prolongee
US9636306B2 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CA2170644C (fr) Preparation pharmaceutique composite renfermant un inhibiteur de pompe a protons
CA2605839C (fr) Composition stabilisee d'un inhibiteur de pompe a protons
NO343175B1 (no) Tablett, granul eller fingranul hvor frigivelse av aktiv ingrediens kontrolleres omfattende en imidazolforbindelse, samt kapsel og utvidet frigivelseskapsel omfattende nevnte tablett, granul eller fingranul
RU2467740C2 (ru) Твердое лекарственное средство с контролируемым высвобождением
KR101908748B1 (ko) 구강내 붕괴정
NO319999B1 (no) Tabletterte, brusende multippelenhet-doseringsformer omfattende en protonpumpeinhibitor, fremgangsmate for fremstilling av slike doseringsformer, og anvendelse derav.
HRP20000381A2 (en) Oral pharmaceutical pulsed release dosage form
EP1420763A1 (fr) Compositions pharmaceutiques stables comprenant des benzimidazoles labiles en milieu acide
JP6364406B2 (ja) 口腔内崩壊錠
WO2010122583A2 (fr) Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
JP2014533656A (ja) 有核錠
CN108135915B (zh) 片剂
WO2013122554A1 (fr) Formulations de pastilles comprenant de l'ésoméprazole
WO2013122553A1 (fr) Formulation pharmaceutique comprenant un inhibiteur d'atpase et procédé de production de cette formulation
KR20100066742A (ko) 안정화된 프로톤 펌프 억제제 함유 약학 조성물
US9040564B2 (en) Stabilized composition
JP4331930B2 (ja) 酸に不安定な薬物の高含量顆粒
JP2015514799A (ja) サルサレートの遅延放出性医薬組成物
JP7321744B2 (ja) 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤
WO2013081566A1 (fr) Formulation comprenant du benzimidazole
KR960015143B1 (ko) 벤즈이미다졸유도체를 함유하는 신규 경구형 제제 및 그 제조방법
TW201323016A (zh) 口腔內崩解錠
MXPA00005896A (en) Oral pharmaceutical extended release dosage form

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13717350

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13717350

Country of ref document: EP

Kind code of ref document: A1